SOUTH SAN FRANCISCO – November 04, 2026 -- IDEAYA Biosciences (NASDAQ: IDYA) will hold an Investor R&D Day in London on Nov. 16, 2026, at 5:00 PM GMT, presenting Phase 1 dose-escalation data for its PRMT5 inhibitor IDE892 and outlining targeted 2027 clinical milestones.
The oncology company will also appear at two sell-side conferences in London that week. CEO Yujiro S. Hata will join a fireside chat at the UBS Global Biopharma Conference on Nov. 16 at 10:40 AM GMT, hosted by Michael Yee. On Nov. 17 at 1:00 PM GMT, Hata, R&D President Michael White and CFO Joshua Bleharski will appear at the Jefferies Global Healthcare Conference, hosted by analyst Maury Raycroft.
R&D Day to detail IDE892 pharmacokinetics, safety and plasma SDMA data
IDEAYA describes IDE892 as a potential best-in-class MTA-cooperative PRMT5 inhibitor. The data summary will cover pharmacokinetics, safety and human plasma SDMA pharmacodynamics from Phase 1 dose escalation. Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center will feature in the event.
CDKN2A program targets an IND submission in the first half of 2027
The company will present preclinical data supporting combination strategies in MTAP/CDKN2A- and RAS-driven pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The planned combinations are:
- IDE892 (PRMT5, Phase 1) in RAS-mutant PDAC
- The CDKN2A program in RAS-mutant PDAC and NSCLC
- IDE574 (KAT6/7, Phase 1) against epigenetic alterations that drive resistance in RAS-mutant CRC and NSCLC
IDEAYA will also outline 2027 clinical data updates and milestones in MTAP/CDKN2A and KRAS, including a PRMT5 and pan-RAS clinical combination.
Registration is mandatory and webcast replays stay online for 30 days
Advance registration is required for both in-person and virtual attendance at the R&D Day. A live audio webcast of the events will run through the Investors/Events section of IDEAYA's website and/or the conference host. Replays will be available for 30 days after the live events.